Integra LifeSciences (NASDAQ:IART) Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts. Key additions to its portfolio include the integration of Derma Sciences’ regenerative wound care products and the acquisition of Johnson & Johnson’s Codman neurosurgery business. These strategic moves have broadened the company’s offerings across dura repair, nerve regeneration and orthopedic extremities.
Integra’s technologies serve a diverse set of clinical settings, including hospitals, outpatient surgical centers and specialty clinics. With a presence in North America, Europe, Asia-Pacific and Latin America, the company maintains manufacturing and distribution operations on multiple continents to support regional product demand and regulatory compliance. Its global footprint allows for collaboration with healthcare professionals on product development and clinical training initiatives.
The company is guided by a management team with extensive experience in medical device innovation, regulatory affairs and commercial operations. Integra continues to invest in research and development, pursuing new applications in tissue engineering and minimally invasive surgery while maintaining a focus on improving patient outcomes and supporting healthcare providers worldwide.
